Jamshed F, Dashti F, Ouyang X, Mehal WZ, Banini BA. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World J Gastroenterol 2023; 29(12): 1824-1837 [PMID: 37032732 DOI: 10.3748/wjg.v29.i12.1824]
Corresponding Author of This Article
Bubu A Banini, MD, PhD, Assistant Professor, Section of Digestive Diseases, Yale School of Medicine, 40 Temple St, Suite 1A, New Haven, CT 06510, United States. bubu.banini@yale.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 28, 2023; 29(12): 1824-1837 Published online Mar 28, 2023. doi: 10.3748/wjg.v29.i12.1824
New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders
Fatima Jamshed, Farzaneh Dashti, Xinshou Ouyang, Wajahat Z Mehal, Bubu A Banini
Fatima Jamshed, Farzaneh Dashti, Xinshou Ouyang, Wajahat Z Mehal, Bubu A Banini, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT 06510, United States
Fatima Jamshed, Griffin Hospital-Yale University, Derby, CT 06418, United States
Wajahat Z Mehal, West Haven Veterans Medical Center, West Haven, CT 06516, United States
Author contributions: The manuscript was outlined and proposed by Banini BA; The literature search, critical assessment of the literature, and writing of the manuscript were performed by Jamshed F, Dashti F, Ouyang X, Mehal WZ, and Banini BA; All authors discussed the manuscript and reviewed and edited the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bubu A Banini, MD, PhD, Assistant Professor, Section of Digestive Diseases, Yale School of Medicine, 40 Temple St, Suite 1A, New Haven, CT 06510, United States. bubu.banini@yale.edu
Received: November 19, 2022 Peer-review started: November 19, 2022 First decision: December 10, 2022 Revised: January 12, 2023 Accepted: March 14, 2023 Article in press: March 14, 2023 Published online: March 28, 2023 Processing time: 129 Days and 5.7 Hours
Core Tip
Core Tip: Digoxin has been used primarily as a cardiac drug for treatment of arrhythmias and heart failure. Preclinical work supports the repurposing of digoxin as therapy for non-cardiac conditions, including alcohol-associated steatohepatitis, nonalcoholic steatohepatitis, obesity and metabolic disorders, autoimmune and inflammatory conditions, malignancy, and viral infections, among others. Here, we provide an overview of findings to date on the potential clinical applications of digoxin and mechanisms of action in steatohepatitis and other non-cardiac disorders. We discuss evidence on the differential action of digoxin at high vs low concentrations and identify areas of further research necessary to harness its promising multifunctional use.
